Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 14, 2013; 19(46): 8678-8686
Published online Dec 14, 2013. doi: 10.3748/wjg.v19.i46.8678
Published online Dec 14, 2013. doi: 10.3748/wjg.v19.i46.8678
Patients with RVR | Patients without RVR | P1value | |
(Group 1,n= 52) | (Group 2,n= 99) | ||
Age (yr) | 55.9 ± 12.2 | 57.9 ± 11.1 | 0.312 |
Male | 24 (46.2) | 51 (51.5) | 0.534 |
Initial ALT (IU/L) | 87.3 ± 109.8 | 52.2 ± 40.4 | 0.005 |
Initial abnormal ALT level | 33 (63.5) | 49 (49.5) | 0.103 |
Initial HCV RNA (log10 IU/ mL) | 5.4 ± 1.1 | 6.1 ± 0.8 | 0.000 |
cEVR | 52 (100) | 58 (59) | 0.000 |
ETR | 48 (92) | 56 (57) | 0.000 |
SVR | 43 (83) | 40 (40) | 0.000 |
ISHAK score, mean ± SD | |||
Biopsy of receipt | 31 (59.6) | 63 (63.6) | 0.631 |
HAI | 8.9 ± 3.8 | 8.2 ± 2.8 | 0.356 |
Fibrosis score | 2.9 ± 1.3 | 2.7 ± 1.4 | 0.681 |
Patients with RVR (Group 1) | P1value | Patients without RVR (Group 2) | P1value | |||
Initial abnormal | Initial normal | Initial abnormal | Initial normal | |||
ALT level | ALT level | ALT level | ALT level | |||
(Group 1h,n= 33) | (Group 1n,n= 19) | (Group 2h,n= 49) | (Group 2n,n= 50) | |||
Age, yr | 54.3 ± 13.8 | 58.6 ± 8.3 | 0.222 | 56.6 ± 12.6 | 59.2 ± 9.2 | 0.246 |
Male | 18 (54.6) | 6 (31.6) | 0.114 | 26 (53.1) | 25 (50.0) | 0.763 |
Initial ALT (IU/ L) | 122.4 ± 125.3 | 26.4 ± 8.2 | 0.002 | 78.1 ± 43.9 | 26.8 ± 7.4 | 0.000 |
HCV RNA (log10 IU/mL) | 5.6 ± 0.9 | 5.1 ± 1.4 | 0.139 | 6.2 ± 0.9 | 6.1 ± 0.7 | 0.748 |
cEVR | 33 (100) | 19 (100) | NA | 29 (59) | 29 (58) | 0.906 |
ETR | 30 (91) | 18 (95) | 0.626 | 26 (53) | 30 (60) | 0.491 |
SVR | 43 (82) | 40 (84) | 0.83 | 18 (37) | 22 (44) | 0.466 |
ISHAK Score, mean ± SD | ||||||
Biopsy of receipt | 17 (51.5) | 14 (73.7) | 0.121 | 33 (67.4) | 30 (60) | 0.453 |
HAI | 9.6 ± 3.7 | 8.0 ± 3.9 | 0.257 | 8.7 ± 2.6 | 7.7 ± 3.0 | 0.164 |
Fibrosis score | 2.9 ± 1.2 | 2.9 ± 1.4 | 0.957 | 3.0 ± 1.4 | 2.4 ± 1.4 | 0.100 |
Initial abnormal ALT level in patients | P2value | Initial abnormal ALT level in patients | P1value | |||
with RVR (Group 1h,n= 33) | without RVR (Group 2h,n= 49) | |||||
Follow-up | Follow-up | Follow-up | Follow-up | |||
abnormal ALT | normalized ALT | abnormal ALT | normalized ALT | |||
After 4 wk | ||||||
No. of patients | 18 | 15 | 29 | 20 | ||
SVR rate | 78 | 87 | 0.525 | 34 | 40 | 0.701 |
After 8 wk | ||||||
No. of patients | 9 | 24 | 18 | 31 | ||
SVR rate | 56 | 88 | 0.049 | 11 | 52 | 0.004 |
After 12 wk | ||||||
No. of patients | 6 | 27 | 17 | 32 | ||
SVR rate | 50 | 89 | 0.028 | 12 | 50 | 0.007 |
After 24 wk | ||||||
No. of patients | 5 | 28 | 15 | 34 | ||
SVR rate | 40 | 89 | 0.001 | 7 | 50 | 0.003 |
After 48 wk | ||||||
No. of patients | 4 | 29 | 17 | 32 | ||
SVR rate | 25 | 90 | 0.006 | 6 | 53 | 0.001 |
After 72 wk | ||||||
No. of patients | 4 | 29 | 21 | 28 | ||
SVR rate | 25 | 90 | 0.006 | 0 | 64 | 0.000 |
- Citation: Dogan UB, Akin MS, Yalaki S. Alanine aminotransferase normalization at week 8 predicts viral response during hepatitis C treatment. World J Gastroenterol 2013; 19(46): 8678-8686
- URL: https://www.wjgnet.com/1007-9327/full/v19/i46/8678.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i46.8678